Immunotherapy Program



Sort by : relevance - date
3Vote!

Studies Show Early Promise Of MannKind's Cancer Immunotherapy Program In Melanoma, Prostate Cancer And Other Solid Malignancies

Melanoma / Skin Cancer NewsStudies Show Early Promise Of MannKind's Cancer Immunotherapy Program In Melanoma, Prostate Cancer And Other Solid MalignanciesAlso Included In: ; Article Date: 02 Nov 2009 - 4:00 PST2 (1 votes)Results of two phase 1 studies demonstrate that the novel, investigational vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response...

4Vote!

Studies Show Early Promise of MannKind’s Cancer Immunotherapy Program in Melanoma, Prostate Cancer and Other Solid Malignancies

... for phase 2 studies. The data are being presented at the International Society for Biological Therapy of Cancer 2009 Annual Meeting. MKC1106-MT is an active immunotherapeutic pr

3Vote!

Elan revenues rise 6%

... million gain arose as a result of a $107.7 million net gain on divestment of the Alzheimer’s Immunotherapy Program (AIP) business to a subsidiary of Johnson & Johnson during the quarter, along with an improved operating performance.During the three-month period ended September 30th, operating loss declined by $29.8 million to $1.7 million as against $31.5 million in the third quarter...

3Vote!

Elan gets subpoena over Tysabri drug

... an 18.4 percent stake in Elan and substantially all of Elan's rights related to an Alzheimer's immunotherapy program.Elan shares fell 21 cents to $7.13 in morning trading in New York.(Reporting by Jonathan Stempel, editing by Gerald E. McCormick)

5Vote!

Johnson & Johnson Buys 18% Stake In Crucell to develop Influenza Treatment

... Johnson & Johnson and Elan Corporation plc merger- Announce Definitive Agreement for Alzheimer’s Immunotherapy Program Johnson & Johnson plans to Arbitrate Remicade Rights With Schering-Plough Roche Provides WHO Additional 5.65 Million Packs Of Tamiflu (oseltamivir) for swine flu!